Literature DB >> 10589744

Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin.

A Abolhoda1, A E Wilson, H Ross, P V Danenberg, M Burt, K W Scotto.   

Abstract

Overexpression of P-glycoprotein (Pgp), a multidrug transporter encoded by the MDR1 gene, is associated with chemoresistance in some human solid tumor malignancies. To date, analyses of MDR1 levels in solid tumors have examined constitutive increases in expression at relapse. In the present study, we have evaluated the acute induction of MDR1 gene expression in a solid human tumor as a function of time in response to in vivo exposure to chemotherapy. Five patients with unresectable sarcoma pulmonary metastases underwent isolated single lung perfusion with doxorubicin. Relative MDR1 gene expression was measured in metastatic tumor nodules and normal lung specimens after initiation of chemoperfusion. In four of five patients, a 3-15-fold (median, 6.8) increase in MDR1 RNA levels was detected in tumors at 50 min after administration of doxorubicin. In contrast, normal lung samples had very low levels of MDR1 RNA prior to perfusion, and no acute increases were observed after therapy. These findings demonstrate, for the first time, that MDR1 gene expression can be rapidly activated in human tumors after transient in vivo exposure to cytotoxic chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10589744

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  58 in total

Review 1.  Neoadjuvant chemoimmunotherapy in locally advanced breast cancer: a new avenue to be explored.

Authors:  Jan Buter; Herbert M Pinedo
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

Review 2.  Emerging role of microRNAs in drug-resistant breast cancer.

Authors:  Sarmila Majumder; Samson T Jacob
Journal:  Gene Expr       Date:  2011

Review 3.  Nanoparticles: a promising modality in the treatment of sarcomas.

Authors:  Michiro Susa; Lara Milane; Mansoor M Amiji; Francis J Hornicek; Zhenfeng Duan
Journal:  Pharm Res       Date:  2010-05-27       Impact factor: 4.200

4.  CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.

Authors:  Juan Liu; Meng Wang; Xiaoli Zhang; Qingwei Wang; Mei Qi; Jing Hu; Zhiqiang Zhou; Chunyan Zhang; Weifang Zhang; Weiming Zhao; Xiao Wang
Journal:  Tumour Biol       Date:  2015-09-24

5.  Nuclear medicine in the treatment of neuroendocrine tumours--problems and perspectives.

Authors:  Tomasz Grzela; Agata Bialoszewska; Robert Brawura-Biskupski-Samaha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04       Impact factor: 9.236

6.  [Role of protein kinase D1 in regulating the growth, apoptosis and drug sensitivity of oral squamous carcinoma cells].

Authors:  Jing-Nan Wang; Ya-Ping Fan; Jiao Chen; Yun Feng; Bo-Miao Cui; Xiao-Ying Li; Li-Wei Wang; Hong-Li Chen; Ping Zhang; Hong-Kun Wu
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2019-12-01

Review 7.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

8.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Authors:  Andreas-Claudius Hoffmann; Peter Wild; Christina Leicht; Simone Bertz; Kathleen D Danenberg; Peter V Danenberg; Robert Stöhr; Michael Stöckle; Jan Lehmann; Martin Schuler; Arndt Hartmann
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

Review 9.  Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.

Authors:  Macus Tien Kuo
Journal:  Antioxid Redox Signal       Date:  2009-01       Impact factor: 8.401

10.  A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.

Authors:  Gene L Bidwell; Aisha N Davis; Izabela Fokt; Waldemar Priebe; Drazen Raucher
Journal:  Invest New Drugs       Date:  2007-05-05       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.